ES2638043T3 - Péptido que mejora la función muscular - Google Patents

Péptido que mejora la función muscular Download PDF

Info

Publication number
ES2638043T3
ES2638043T3 ES10714584.9T ES10714584T ES2638043T3 ES 2638043 T3 ES2638043 T3 ES 2638043T3 ES 10714584 T ES10714584 T ES 10714584T ES 2638043 T3 ES2638043 T3 ES 2638043T3
Authority
ES
Spain
Prior art keywords
seq
peptide
muscle
calcium
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10714584.9T
Other languages
English (en)
Spanish (es)
Inventor
Patrick Most
Mirko Voelkers
Hugo Katus
Andrew Remppis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universität Heidelberg
Original Assignee
Universität Heidelberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universität Heidelberg filed Critical Universität Heidelberg
Application granted granted Critical
Publication of ES2638043T3 publication Critical patent/ES2638043T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4728—Calcium binding proteins, e.g. calmodulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ES10714584.9T 2009-04-16 2010-04-16 Péptido que mejora la función muscular Active ES2638043T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US169962P 1999-12-09
US16996209P 2009-04-16 2009-04-16
PCT/EP2010/002343 WO2010118878A1 (en) 2009-04-16 2010-04-16 Muscle function enhancing peptide

Publications (1)

Publication Number Publication Date
ES2638043T3 true ES2638043T3 (es) 2017-10-18

Family

ID=42226606

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10714584.9T Active ES2638043T3 (es) 2009-04-16 2010-04-16 Péptido que mejora la función muscular

Country Status (7)

Country Link
US (1) US9428564B2 (enExample)
EP (1) EP2419119B1 (enExample)
JP (1) JP5847073B2 (enExample)
CN (1) CN102395377B (enExample)
CA (1) CA2756249C (enExample)
ES (1) ES2638043T3 (enExample)
WO (1) WO2010118878A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6068347B2 (ja) * 2010-10-20 2017-01-25 ルプレクト−カールズ−ウニベルシタット ハイデルベルク 筋機能を増強させる短ペプチド
EP3052118A1 (en) * 2013-10-01 2016-08-10 Ruprecht-Karls-Universität Heidelberg S100 based treatment of cardiac power failure
CN117589740B (zh) * 2024-01-04 2025-02-11 南京市产品质量监督检验院(南京市质量发展与先进技术应用研究院) 一种高通量快速检测和评估化合物骨骼肌毒性的方法
WO2026132516A1 (en) 2024-12-20 2026-06-25 Patrick Most S100a1 protein-derived peptide for use in treating cancer or in treating or preventing antineoplastic agent-mediated cytotoxicity, cancer therapy-related cardiac dysfunction or cancer therapy related heart failure

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7553929B2 (en) * 1994-06-13 2009-06-30 Vanderbilt University Cell permeable peptides for inhibition of inflammatory reactions and methods of use
GB9614871D0 (en) * 1996-07-15 1996-09-04 Smithkline Beecham Plc Compounds
DE19915485A1 (de) * 1999-04-07 2000-10-19 Hugo A Katus Therapie der Herzinsuffizienz

Also Published As

Publication number Publication date
US20120129758A1 (en) 2012-05-24
CN102395377B (zh) 2016-10-19
EP2419119A1 (en) 2012-02-22
JP5847073B2 (ja) 2016-01-20
CA2756249A1 (en) 2010-10-21
WO2010118878A1 (en) 2010-10-21
EP2419119B1 (en) 2017-06-07
CN102395377A (zh) 2012-03-28
JP2012524034A (ja) 2012-10-11
US9428564B2 (en) 2016-08-30
CA2756249C (en) 2020-08-18

Similar Documents

Publication Publication Date Title
ES2887042T3 (es) Moduladores del receptor S1P para el tratamiento de la esclerosis múltiple
Petrof The molecular basis of activity-induced muscle injury in Duchenne muscular dystrophy
Conte et al. Growth hormone secretagogues prevent dysregulation of skeletal muscle calcium homeostasis in a rat model of cisplatin‐induced cachexia
ES2399741T3 (es) Oxintomodulina para la prevención o el tratamiento del sobrepeso
JP3809184B2 (ja) 虚血関連ニューロン損傷を処置するための組成物
JP2019089773A (ja) ミトコンドリア透過性転移の阻止方法
JP2020196762A (ja) 熱傷及び二次性合併症の予防及び治療方法
US20160151461A1 (en) Cardio-Metabolic and Vascular Effects of GLP-1 Metabolites
Guan Insulin-like growth factor-1 and its derivatives: potential pharmaceutical application for ischemic brain injury
US20070123453A1 (en) Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continuous infusion
US20150151000A1 (en) Peptide conjugates for treating pain
CA2756249C (en) Muscle function enhancing peptide derived from s100 protein
CA2814967C (en) Short peptides for enhancing muscle function
ES2870106T3 (es) Moduladores de la comunicación intercelular de uniones comunicantes y su uso para el tratamiento de la enfermedad del ojo diabético
ES2861502T3 (es) Anestesia y analgesia locales y regionales
US20130196925A1 (en) Compositions and methods useful in enhancement of memory
JP2018509395A (ja) 筋肉の疾患および障害を治療するための方法および組成物
US20250262272A1 (en) Peptides and methods of use thereof in treating skin diseases
JP2022544718A (ja) 敗血症性心筋症を治療するための組成物および方法
HU206185B (en) Process for producing pharmaceutical compositions suitable for causing or hindering pupillary contraction
Pisarenko et al. 5-Hydroxydecanoate abolishes cardioprotective effects of a structural analogue of apelin-12 in ischemia/reperfusion injury
HK1167331B (en) Muscle function enhancing peptide
HK1167331A (en) Muscle function enhancing peptide
Bers Na/Ca exchange and the sarcolemmal Ca-pump
JP5861215B2 (ja) 神経ペプチドを用いた神経因性疼痛軽減薬剤ならびに抗うつ薬剤